These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28264791)

  • 1. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
    Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
    Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
    Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
    Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to biologicals in Crohn's disease in ten European countries.
    Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
    World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.
    Cherny N; Sullivan R; Torode J; Saar M; Eniu A
    Ann Oncol; 2016 Aug; 27(8):1423-43. PubMed ID: 27457309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma prognosis in Europe: far from equal.
    Forsea AM; Del Marmol V; Stratigos A; Geller AC
    Br J Dermatol; 2014 Jul; 171(1):179-82. PubMed ID: 24588115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
    Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
    Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
    Leccia MT; Planchamp F; Sassolas B; Combemale P; Modiano P; Bedane C; Cupissol D; Derrey S; Dygai-Cochet I; Lamant L; Lubrano V; Mirabel X; Mourrégot A; Rougé Bugat ME; Siegrist S; Thariat J; Tiffet O; Truc G; Verdoni L; Mazeau-Woynar V
    Ann Dermatol Venereol; 2014 Feb; 141(2):111-21. PubMed ID: 24507205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries.
    McKendrick J; Gijsen M; Quinn C; Barber B; Zhao Z
    J Med Econ; 2016 Jun; 19(6):587-95. PubMed ID: 26823114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
    Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
    Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New treatments for metastatic melanoma: a first hope].
    Robert C; Mateus C
    Rev Prat; 2011 Nov; 61(9 Suppl):S1-2. PubMed ID: 22338196
    [No Abstract]   [Full Text] [Related]  

  • 11. Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries.
    Vogler S; Österle A; Mayer S
    Int J Equity Health; 2015 Nov; 14():124. PubMed ID: 26541292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-of-illness of melanoma in Europe - a modelling approach.
    Krensel M; Schäfer I; Augustin M
    J Eur Acad Dermatol Venereol; 2019 Mar; 33 Suppl 2():34-45. PubMed ID: 30811699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inequities in access to biologic and synthetic DMARDs across 46 European countries.
    Putrik P; Ramiro S; Kvien TK; Sokka T; Pavlova M; Uhlig T; Boonen A;
    Ann Rheum Dis; 2014 Jan; 73(1):198-206. PubMed ID: 23467636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
    Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
    Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force.
    Garbe C; Peris K; Soura E; Forsea AM; Hauschild A; Arenbergerova M; Bylaite M; Del Marmol V; Bataille V; Samimi M; Gandini S; Saiag P; Eigentler TK; Lallas A; Zalaudek I; Lebbe C; Grob JJ; Hoeller C; Robert C; Dréno B; Arenberger P; Kandolf-Sekulovic L; Kaufmann R; Malvehy J; Puig S; Leiter U; Ribero S; Papadavid E; Quaglino P; Bagot M; John SM; Richard MA; Trakatelli M; Salavastru C; Borradori L; Marinovic B; Enk A; Pincelli C; Ioannides D; Paul C; Stratigos AJ
    J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2183-2197. PubMed ID: 32840022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.